© Reuters.
NEW YORK (Reuters) – A federal appeals court on Tuesday revived a lawsuit by a whistleblower who accused McKesson (NYSE:) of providing drug pricing tools to doctors to induce them to purchase drugs from the company.
The decision by the 2nd U.S. Circuit Court of Appeals in Manhattan restores claims by Adam Hart, a former McKesson business development executive.
This article was written byFollowI am an investment professional with over 7 years of experience spanning quant equities, asset management,...
Irregulars Quick Take Paid members get a quick summary of the stocks teased and our thoughts here. Join as a...
Greg Abel, CEO of Berkshire Hathaway, speaks during the Berkshire Hathaway Annual Shareholders Meeting in Omaha, Nebraska, May 2, 2026.CNBCBerkshire...
The S&P 500 dividend yield just hit an all-time low of 1.08%, the lowest since the 1800s. The prior low...
By Kamal Choudhury and Christy Santhosh April 29 (Reuters) - on Wednesday reported better-than-expected quarterly revenue and profit, fueled by...
Get the latest news and follow the coverage of Investing, World News, Stocks, Market Analysis, Business & Financial News, and more from the top trusted sources.
